

More childhood cancer diagnoses than expected: Incidence, time of diagnosis and delivery of healthcare among children with cancer in Germany during the COVID-19 pandemic

Friederike Erdmann, PhD, MPH

Head, Research Group Aetiology and Inequalities in Childhood Cancer

Division of Childhood Cancer Epidemiology

Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center Mainz

Workshop der AG Krebsepidemiologie (DGEpi) und des Epidemiologischen Krebsregisters Niedersachsen, COVID & Krebs, 26.10.2023



Following the outbreak of the COVID-19 pandemic...

- In many countries, healthcare authorities advised to delay care for non-acute or not lifethreatening conditions
- Healthcare services (for non-communicable diseases) have been severely disrupted in the beginning of the COVID-19 pandemic.

 Remarkable decline in new cancer diagnoses as well as evidence for missed and delayed diagnoses, delayed treatment and rises in cancer deaths have been noted - also specifically

for childhood cancers.

• **Timely diagnosis is essential** for good prognosis and preventing advanced disease, which commonly requires more intensive therapy.

Causes of childhood cancers remain largely unknown

Weak or no effect of parental behaviour and diet







No established environmental causes, but...









Possible role of infections/ immune system in childhood leukaemia





- → increasing concern about the indirect impact on cancer care and timely diagnosis
- → scientific interest of the impact of the pandemic with its social distancing measures on the risk of children of developing B-precursor ALL





Closure of nurseries, kindergartens, and schools

Lack of immune system stimulation during infancy



+ Risk

Removed older susceptible children from exposure to common infectious agents



- Risk

Design

Quantitative assessment

• to quantify numbers of newly diagnosed cases of childhood cancer reported to the German Childhood Cancer Registry and estimate incidence rates of childhood cancers

Qualitative survey

• to explore the perceptions of paediatric oncologists of (i) the diagnostic process and timeliness of diagnosis, (ii) the delivery of healthcare including the provision of psychosocial supportive care and overall changes in structures and processes of healthcare provision in response to the COVID-19 pandemic

Methods


Quantitative assessment:

- Analysis of newly diagnosed cases of childhood cancer in Germany at ages 0-14 and 0-17 in 2020 and 2021
- Absolute numbers for each month of 2020 compared to the previous five years (2015-2019)
- Age-standardised incidence rates in 2020 and 2021 compared to the previous five years (2015-2019)


Qualitative survey:

- Survey with open-ended questions: Invitation to 16 paediatric haematology-oncology units (response: 75%)
- Qualitative content analysis to analyse the responses to the open-ended questions

Absolute numbers of newly diagnosed childhood cancer cases in 2020 vs. the average numbers of childhood cancer cases during 2015-2019



Absolute numbers of newly diagnosed lymphoid leukaemia cases in 2020 vs. the average numbers of childhood cancer cases during 2015-2019



Estimated age-standardised incidence rates of childhood cancer in Germany in 2020

	0-14 years ASR per 1,000,000 [95% CI]			0-17 years		
				ASR per 1,000,000 [95% CI]		
	2015-2019	2020	% 👚	2015-2019	2020	% 👚
All cancers	172.8 [169.3-176.4]	190.5 [182.4-198.7]	10.2%	171.3 [168.1-174.5]	191.0 [183.6-198.5]	11.5%
Leukaemias	55.2 [53.2-57.2]	61.2 [56.7-65.9]	10.9%	51.5 [49.8-53.3]	56.9 [52.9-61.1]	10.3%
Lymphoid leukaemia	43.1 [41.3-44.9]	47.6 [43.6-51.7]	10.4%	39.2 [37.7-40.7]	43.2 [39.7-46.8]	10.2%
Lymphomas	21.2 [20.0-22.4]	23.7 [21.0-26.6]	11.8%	26.1 [24.9-27.3]	30.0 [27.2-32.9]	14.9%
CNS tumours	41.2 [39.6-43.0]	46.2 [42.3-50.3]	12.1%	39.3 [37.8-40.8]	44.5 [41.0-48.2]	13.5%
Non-CNS solid tumours	55.2 [53.2-57.2]	59.3 [54.8-64.0]	7.6%	54.3 [52.5-56.1]	59.5 [55.4-63.8]	9.8%

Qualitative content analysis – key findings

Diagnostic process/ timeliness of diagnosis

• Diagnostic processes, timeliness of diagnosis, delivery of treatment hardly affected

Delivery of healthcare for children with cancer

 Psychosocial supportive care and non-urgent appointments such as long-term follow-up care of survivors markedly reduced during the lockdown periods

<u>Overall:</u> Disruptions seemed to differ between the first and the second lockdown, and the inter-lockdown period.

Estimated age-standardised incidence rates of childhood cancer in Germany in 2021

	0-14 years			0-17 years		
	ASR per 1,000,000 [95% CI]			ASR per 1,000,000 [95% CI]		
ICCC-3 diagnostic group	2015-2019	2020	2021	2015-2019	2020	2021
All cancers	172.8	190.5	174.0	171.3	191.0	175.9
	[169.3-176.4]	[182.4-198.7]	[166.3-181.8]	[168.1-174.5]	[183.6-198.5]	[168.9-183.1]
Leukaemias	55.2	61.2	58.9	51.5	56.9	56.0
	[53.2-57.2]	[56.7-65.9]	[54.4-63.5]	[49.8-53.3]	[52.9-61.1]	[52.1-60.2]
Lymphoid leukaemia	43.1	47.6	44.8	39.2	43.2	40.8
	[41.3-44.9]	[43.6-51.7]	[40.9-48.8]	[37.7-40.7]	[39.7-46.8]	[37.4-44.4]
Acute myeloid	7.3	7.8	8.3	7.3	7.7	8.7
leukaemia	[6.6-8.1]	[6.2-9.6]	[6.7-10.1]	[6.6-7.9]	[6.2-9.3]	[7.2-10.3]
Lymphomas	21.2	23.7	18.5	26.1	30.0	<mark>24.9</mark>
	[20.0-22.4]	[21.0-26.6]	[16.1-21.0]	[24.9-27.3]	[27.2-32.9]	[22.4-27.5]
CNS tumours	41.2	46.2	43.9	39.3	44.5	42.3
	[39.6-43.0]	[42.3-50.3]	[40.1-47.8]	[37.8-40.8]	[41.0-48.2]	[38.9-45.8]
Non-CNS solid tumours	55.2	59.3	<mark>52.8</mark>	54.3	59.5	<mark>52.7</mark>
	[53.2-57.2]	[54.8-64.0]	[48.6-57.2]	[52.5-56.1]	[55.4-63.8]	[48.8-56.7]

Estimated age-standardised incidence rates of B-cell precursor ALL

B-cell precursor acute lymphoblastic leukaemia age-specific incidence rate per 1,000,000 [95% CI]							
	2005-2009	2010-2014	2015-2019	2020	2021		
2-6 years of age	72.7 [68.8-76.7]	70.2 [66.3-74.2]	72.2 [68.3-76.2]	79.1 [70.6-88.4] 9.6%	68.1 [60.3-76.7]		
7-14 years of age	23.8 [22.2-25.6]	22.5 [20.8-24.3]	22.8 [21.1-24.6]	24.4 [20.6-28.8] 7.0 %	23.4 [19.7-27.6]		

Discussion



- No decrease in newly diagnosed childhood cancer cases in Germany during the COVID-19
 pandemic that would suggest missed or (considerably) delayed diagnoses
- Diagnostic processes, timeliness of diagnosis, delivery of treatment hardly affected
- Psychosocial supportive care and non-urgent appointments markedly reduced during the lockdown periods
- (Unexpected) marked increase in incidence rates in 2020, across all diagnostic groups, followed by a regression for most cancer types

Discussion

• Underlying reasons of the increase in incidence in 2020 are speculative, may **involve greater parental attention** and physician's awareness to early disease symptoms and hence **more timely healthcare consultations and earlier diagnoses.**



- The indications of a potential rebound effect in the 2021 for lymphoma and non-CNS solid tumours but not for other diagnostic groups, speaks however against this as the only explanation.
- Continued increase in the incidence of CNS tumours: improvements in completeness of reporting?

Leukemia www.nature.com/leu

lood ndemic:





Additional slides

Decline in new cancer diagnoses for childhood cancer


Inconsistent observations for paediatric cancer

- Stable number of children diagnosed with cancer (Greece)
- Substantially fewer diagnoses than expected (USA, Italy)
- Decrease in some diagnostic groups or cancer types but not in others (USA, Norway)
- Only a snapshot, limited by small sample sizes of mostly institutional or regional data and capturing only the period of the first pandemic wave



1,551 new ALL cases projected in 2-6-year-old children in Germany during the 2020-2024 period







1 out of 15
ALL cases
attributed to COVID-19



6.4 %

of the total ALL cases might be attributable to the lockdown of childcare facilities

The German Childhood Cancer Registry



- Established 1980 at the Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center Mainz
- Nationwide population-based cancer registry
- Collecting data on incident diagnoses of cancers in children and adolescents (aged 0-17 years) with place of residence in Germany
- Defined according to ICCC-3, including non-malignant CNS tumours
- ~2250 incident cases every year